Ao C, Huo Y, Qi L, Xiong Z, Xue L, Qi Y.
Thiazolidinediones (TZDs) are prescribed as anti-type II diabetes drugs, but little is known regarding whether TZDs regulate the expression of secretory phospholipase A2 (sPLA2) in macrophage. We have investigated the effects of pioglitazone on LPS-induced production of tumor necrosis factor alpha (TNF-alpha), group V and X sPLA2(sPLA2-V and -X) in RAW 264.7 macrophage. TNF-alpha, sPLA2-V and sPLA2-X mRNA and protein expression was determined by RT-PCR and Western blot analysis, respectively. The activity of nuclear factor kappaB (NF-kappaB) was determined by Western blot and confocal microscopy. LPS induced TNF-alpha, sPLA2-V and sPLA2-X mRNA and protein expression. Pretreatment with 10 mumol/L pioglitazone significantly suppressed LPS-induced TNF-alpha, sPLA2-V and sPLA2-X mRNA and protein expression. LPS induced NF-kappaB expression and translocation in the nucleus, but the inductive effects was inhibited by pioglitazone. Our findings indicate that pioglitazone inhibits production of inflammatory factors induced by LPS in murine macrophage cells by inactivating NF-kB. Pioglitazone appears to play an anti-inflammatory role in atherosclerosis process.
PMID: 19947950
| < Prev | Next > |
|---|
